The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

MLA

Loomba, Rohit, et al. “The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.” Hepatology (Baltimore, Md.), vol. 67, no. 2, Feb. 2018, pp. 549–59. EBSCOhost, https://doi.org/10.1002/hep.29514.

APA

Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., Subramanian, G. M., McHutchison, J. G., Goodman, Z. D., Afdhal, N. H., & Charlton, M. R. (2018). The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology (Baltimore, Md.), 67(2), 549–559. https://doi.org/10.1002/hep.29514

Chicago

Loomba, Rohit, Eric Lawitz, Parvez S Mantry, Saumya Jayakumar, Stephen H Caldwell, Hays Arnold, Anna Mae Diehl, et al. 2018. “The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial.” Hepatology (Baltimore, Md.) 67 (2): 549–59. doi:10.1002/hep.29514.